A prospective randomized study of the comparison intravesical BCG therapy with intravesical chemotherapy using pirarubicin for non muscle invasive bladder cancer with intermediate recurrent risk
Not Applicable
- Conditions
- Bladder Cancer
- Registration Number
- JPRN-UMIN000022153
- Lead Sponsor
- Kyoto Prefectural University of Medicine, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 116
Inclusion Criteria
Not provided
Exclusion Criteria
1.Active double cancer (including upper urinary tract carcinoma and prostate carcinoma) 2. CIS, High grade or MIBC confirmed TURBT 3. Previously received BCG intravesical chemotherapy or intravesical chemotherapy within 1 year 4. Serious drug hypersensitivity 5. Active tuberculosis defined by T spot 6. Severe dysfuction of main organs, CHF with NYHA III or IV, asparates aminotransferase and alanine amonotransferase below 3 times as normal values, Hb A1c >= 8.0% 7. Serious viral and bacterial infection 8. Patients the investigators considered to be inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of adverse effects
- Secondary Outcome Measures
Name Time Method 2 Year recurrent free rate